BR112022013167A2 - Pastilha - Google Patents

Pastilha

Info

Publication number
BR112022013167A2
BR112022013167A2 BR112022013167A BR112022013167A BR112022013167A2 BR 112022013167 A2 BR112022013167 A2 BR 112022013167A2 BR 112022013167 A BR112022013167 A BR 112022013167A BR 112022013167 A BR112022013167 A BR 112022013167A BR 112022013167 A2 BR112022013167 A2 BR 112022013167A2
Authority
BR
Brazil
Prior art keywords
nicotine
lozenge
tablet
absorption
cravings
Prior art date
Application number
BR112022013167A
Other languages
English (en)
Inventor
Thyresson Kristina
Lindell Katarina
Original Assignee
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ab filed Critical Mcneil Ab
Publication of BR112022013167A2 publication Critical patent/BR112022013167A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

PASTILHA. Esta invenção se refere a uma pastilha de nicotina que fornece liberação e absorção imediatas de nicotina e liberação e absorção prolongadas de nicotina, bem como descreve processos de fabricação adequados para tais formulações de pastilhas e o uso da pastilha para o tratamento de um ser humano que sofre de desejos causados pela dependência de tabaco e/ou cigarro.
BR112022013167A 2020-01-15 2021-01-14 Pastilha BR112022013167A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2050030 2020-01-15
PCT/EP2021/050705 WO2021144367A1 (en) 2020-01-15 2021-01-14 Lozenge

Publications (1)

Publication Number Publication Date
BR112022013167A2 true BR112022013167A2 (pt) 2022-09-13

Family

ID=74285439

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013167A BR112022013167A2 (pt) 2020-01-15 2021-01-14 Pastilha

Country Status (8)

Country Link
US (1) US20230053622A1 (pt)
EP (1) EP4090314A1 (pt)
CN (1) CN115003281A (pt)
AU (1) AU2021207268A1 (pt)
BR (1) BR112022013167A2 (pt)
CA (1) CA3167882A1 (pt)
MX (1) MX2022008739A (pt)
WO (1) WO2021144367A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076211A1 (en) * 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
US20070269492A1 (en) 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20080286341A1 (en) 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
WO2019244176A1 (en) * 2018-06-23 2019-12-26 Strides Shasun Limited Stable nicotine lozenges

Also Published As

Publication number Publication date
MX2022008739A (es) 2022-10-07
CA3167882A1 (en) 2021-07-22
AU2021207268A1 (en) 2022-09-08
EP4090314A1 (en) 2022-11-23
US20230053622A1 (en) 2023-02-23
CN115003281A (zh) 2022-09-02
WO2021144367A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
CL2021000387A1 (es) Compuestos de anillo fusionado
CO2021005987A2 (es) Compuestos de anillo fusionado
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
CO6410316A2 (es) Sistema de generación de aerosol de nicotina a base de tabaco
CL2021000514A1 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
CL2004000257A1 (es) Compuestos heterociclil-3-sulfonilaza-indol o -indazol; su composicion farmaceutica; su procedimiento de preparacion; y su uso en el tratamiento de trastornos por deficit atencional, abstinencia producto de la adiccion a drogas, alcohol o nicotina, e
ECSP066608A (es) Suspensiones acuosas de ciclesonide para nebulización
UA112411C2 (uk) Пригнічення подразнення рецепторів при споживанні бездимних тютюнових виробів
NO20070686L (no) 17-Desmetylrapamucin og analoger av det, framgangsmater for framstilling av disse, og bruk av disse som immunosupressanter, antikreft-forbindelser, soppdrepende forbindelser, osv
CL2019000485A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional.
ATE341952T1 (de) Verfahren und zusammensetzung zur mentholanreicherung von zigaretten
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
MX2016010373A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
UY29161A1 (es) Nuevos heterociclos
MX2020013832A (es) Conjugados de ligante/agente activo dirigidos contra cxcr5 que tienen enlazadores escindibles enzimaticamente y un perfil de actividad mejorado.
UY37971A (es) Derivados de indol macrocíclicos sustituidos
MX2021008536A (es) Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa.
UY29189A1 (es) Nonadepsipeptidos acilados ii
UY28313A1 (es) Nonadepsipeptidos acilados
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
MX2022002859A (es) Articulos y formulaciones para vaporizadores y productos para fumar.
BR112023015272A2 (pt) Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
BR112022013167A2 (pt) Pastilha
BR112022013163A2 (pt) Produto e processo de fabricação de uma goma